Research and Markets (http://www.researchandmarkets.com/research/6bnh4h/hiv1_infection) has announced the addition of the "HIV-1 Infection - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for HIV-1 Infection.
The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Reasons to buy:
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline
Companies Mentioned:
- AltraVax Inc.
- Aphios Corporation
- Argos Therapeutics, Inc.
- Arno Therapeutics, Inc.
- Beth Israel Deaconess Medical Center, Inc.
- Bionor Pharma ASA
- Biosantech SA
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Chipscreen Biosciences Ltd
- CompleGen, Inc.
- Critical Outcome Technologies Inc.
- Cytodyn Inc.
- Dong-A ST Co., Ltd.
- Enzo Biochem, Inc.
- Evofem, Inc.
- FIT Biotech Oy
- Formune S.L.
- Frontier Biotechnologies Co., Ltd
- GeneCure LLC
- Genetic Immunity, Inc
- Gilead Sciences, Inc.
- GlaxoSmithKline Plc
- H-Phar S.A.
- Heat Biologics, Inc.
-
(20+ Others)
For more information visit http://www.researchandmarkets.com/research/6bnh4h/hiv1_infection
View source version on businesswire.com: http://www.businesswire.com/news/home/20160127005977/en/